1. Biomarkers and surrogate endpoints in clinical trials;Fleming;Stat Med,2012
2. National Lipid Association Annual Summary of Clinical Lipidology 2016;Bays;J Clin Lipidol,2016
3. FDA. Guidance for Industry: Evidence-based review system for the scientific evaluation of health claims – final. Available at: http://www.fda.gov/Food/GuidanceRegulation/GuidanceDocumentsRegulatoryInformation/LabelingNutrition/ucm073332.htm. Accessed December 23, 2016.
4. FDA. Biomarkers used as outcomes in development of FDA-approved therapeutics (October 2007–December 2015). Available at: http://www.fda.gov/drugs/developmentapprovalprocess/drugdevelopmenttoolsqualificationprogram/ucm483052.htm. Accessed December 23, 2016.
5. Attenuation of rate of change in carotid intima-media thickness by lipid-modifying drugs;Peters;Am J Cardiovasc Drugs,2011